JEWJITSU PEPTIDES Research Roundup: programmable degraders, Ang-(1-7) vesicles, and AgNP+CM11 antibacterial synergy

A study reported the development of designer ubiquibodies (uAbs) that combine an E3 ubiquitin ligase domain with computationally designed guide peptides to target β-catenin. The authors used a protein language model algorithm called SaLT&PepPr to design peptide guides, fused those peptides to the catalytic domain of a human E3 ligase, and screened constructs in colorectal cancer cells. Several uAb designs reduced the pool of cytosolic and nuclear β-catenin while sparing membrane‑associated β-catenin, with downstream suppression of Wnt/β‑catenin signaling and impaired tumor cell proliferation in vitro. The report also describes in vivo delivery of one degrader as lipid nanoparticle‑encapsulated mRNA that selectively lowered cytosolic but not membrane β‑catenin in mouse liver. These are preclinical findings reported by the authors; translation to clinical use would require additional validation, safety assessment, and demonstration of efficacy in relevant models beyond those presented.

The second paper describes that Angiotensin‑(1‑7) stimulates cardiomyocytes to release small extracellular vesicles (sEVAng-(1-7)) that the authors found to have enhanced cardioprotective activity compared with Ang‑(1‑7) alone. In mouse models of myocardial ischemia/reperfusion injury, including mice with cardiac Mas receptor knockout, enriched sEVAng-(1-7) were reported to preserve cardiac function and reduce cardiomyocyte apoptosis and oxidative stress. In human AC16 cardiomyocytes subjected to hypoxia/reoxygenation, enriched sEVAng-(1-7) were associated with increased Akt2 phosphorylation, greater SERCA activity and improved calcium handling, reduced ER stress marker signaling, and protection against apoptosis; Akt2 knockdown attenuated those benefits. The authors emphasize a largely Mas receptor‑independent mechanism. As presented, this work is preclinical and mechanistic; further work is needed to establish safety, dosing, and relevance in human disease contexts.

The third report examined green synthesis of silver nanoparticles (AgNPs) using Rosa damascena extract and tested antibacterial activity of the AgNPs and a cationic CM11 peptide. The nanoparticles were characterized by standard physicochemical techniques described by the authors, and antibacterial activity was assessed by broth microdilution and checkerboard assays. Both AgNPs and CM11 showed inhibitory activity against multidrug‑resistant and colistin‑resistant isolates in vitro, and the combination produced synergistic, partially synergistic, or additive interactions against various tested strains. These results indicate in‑vitro antibacterial potential and combination effects as reported; however, the study is limited to laboratory assays and characterization, so implications for clinical treatment, safety, pharmacokinetics, and in vivo efficacy were not established in the report.